Methylprednisolone aceponate
Akrikhin
1450 Items
2019-09-19
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
GKS for external use. Suppresses the function of leukocytes and tissue macrophages. Limits the migration of leukocytes to the area of inflammation. Violates the ability of macrophages to phagocytosis, as well as the formation of interleukin-1. It contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the area of inflammation. Reduces capillary permeability due to histamine release. Suppresses the activity of fibroblasts and the formation of collagen.
Inhibits the activity of phospholipase A2, which leads to the suppression of the synthesis of prostaglandins and leukotrienes. Suppresses the release of COX (mainly COX-2), which also helps to reduce the production of prostaglandins.
Reduces the number of circulating lymphocytes (T-and B-cells), monocytes, eosinophils and basophils due to their movement from the vascular bed to the lymphoid tissue; inhibits the formation of antibodies.
Methylprednisolone aceponon suppresses pituitary ACTH and? -Lipotropin release, but does not reduce the level of circulating? -Endorphine. Inhibits the secretion of TSH and FSH.
When applied directly to the vessels, it causes a vasoconstrictor effect.
When applied topically and locally, the therapeutic activity of methylprednisolone is due to the anti-inflammatory, antiallergic and anti-exudative (due to the vasoconstrictor effect) action.
Indications
- Inflammatory skin diseases sensitive to therapy with topical glucocorticosteroids:
- atopic dermatitis, neurodermatitis, children eczema;
- true eczema;
- microbial eczema
- professional eczema;
- simple contact dermatitis;
- allergic (contact) dermatitis;
- dishydrotic eczema.
Composition
| 100 g | |
| methylprednisolone aceponate (in terms of 100% substance) | 100 mg |
Excipients: petrolatum - 44.7 g, liquid paraffin - 34.1 g, castor oil seed oil - 3.2 g, white beeswax - 17.9 g.
Methylprednisolone aceponate is marketed under different brands and generic names, and comes in different dosage forms:
| Brand name | Manufacturer | Country | Dosage form |
|---|---|---|---|
| Comfoderm K | Akrikhin | Russia | ointment |
| Advantan | Bayer Pharma AG | Germany | ointment |
| Advantan | Bayer Pharma AG | Germany | emulsion |
| Advantan | Bayer Pharma AG | Germany | cream |
No customer reviews for the moment.
Dosage and Administration
Apply externally 1 time / day with a thin layer on the affected area, slightly rubbing. Use with an occlusive dressing is possible. Typically, the treatment is for adults no more than 12 weeks, and for children - no more than 4 weeks. Several courses of therapy are possible throughout the year.
Contraindications
uberculous or syphilitic processes in the field of drug application; viral diseases (for example, chicken pox, shingles) in the area of application of the drug;
rosacea, perioral dermatitis in the area of application of the drug; children's age up to 4 months;
skin areas with reactions to vaccination; hypersensitivity to the drug.
Use during pregnancy and during breastfeeding
If necessary, the use of the drug Komfoderm® during pregnancy and during breastfeeding should carefully weigh the potential risk to the fetus and the expected benefit of treatment for the mother. During these periods, prolonged use of the drug on the extensive surfaces of the skin is not recommended; nursing mothers should not apply the drug to the mammary glands.
Overdosage
When studying the acute toxicity of megilprednisolone aceponate, there was no risk of acute intoxication with excessive single skin application (application of the drug over a large area under conditions favorable for absorption) or unintentional ingestion. With excessively long and / or intensive use of glucocorticosteroids for paired use, skin atrophy may develop (thinning of the skin, telangiectasia, striae)
- Brand name: Comfoderm K
- Active ingredient: Methylprednisolone aceponate
- Dosage form: Ointment for external use 0.1% from white or to white with a grayish or yellowish shade of color, the presence of a characteristic odor.
- Manufacturer: Akrikhin
- Country of Origin: Russia
Studies and clinical trials of Methylprednisolone aceponate (Click to expand)
- Wirksamkeit und Verträglichkeit von Methylprednisolonaceponat (Advantan®) in der Behandlung ekzematöser Erkrankungen im Gesicht : Effectiveness and tolerability of methylprednisolone aceponate (Advantan®) in the treatment of eczematous disorders of the face
- Allergic contact dermatitis caused by 6α-methylprednisolone aceponate
- Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study
- Methylprednisolone aceponate* in eczema and other inflammatory skin disorders – a clinical update
- Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis
- Allergic contact dermatitis to methylprednisolone aceponate in a topical corticosteroid
- Segmental lichen aureus: A report of two cases treated with methylprednisolone aceponate
- B-Scanning assessment of the anti-inflammatory activity of methylprednisolone aceponate on experimentally induced allergic reactions
- Overview of clinical experience with methylprednisolone aceponate
- Skin atrophogenic potential of methylprednisolone aceponate (MPA)
- Long-term treatment with 6α-methylprednisolone aceponate
- Clinical comparison of methylprednisolone aceponate and prednicarbate in chronic eczema
- Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate
- Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate
- Allergic contact dermatitis from 6α-methylprednisolone aceponate and budesonide
- Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate
- Allergic contact dermatitis caused by 6α-methylprednisolone aceponate
- Preclinical evaluation of a new topical corticosteroid methylprednisolone aceponate
- Frontiers of rapid itch relief: a review of methylprednisolone aceponate
- Effective use of methylprednisolone aceponate 0.1% in a 9-month-old infant with atopic eczema and sleep disturbance
- Successful treatment of widespread eczema and sleep disruption in a 7-month-old infant with methylprednisolone aceponate 0.1%
- Methylprednisolone aceponate 0.1% in the treatment of pruritic lichenified eczema in a 3-year-old child with chronic atopic dermatitis
- Alleviation of a severe pruritic flare-up in a 13-year-old child with chronic atopic dermatitis treated with methylprednisolone aceponate 0.1%
- Methylprednisolone aceponate
8 other products in the same category:
arrow_upward